Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

546
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
546
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.0K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

2.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

392
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
392

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Hemoglobin Levels: Integrating Anemia Phenotyping Into Prognostic Models for Patients With Stroke Following Intravenous Thrombolysis.

Journal of the American Heart Association·2026
Same author

Cerebral Venous Thrombosis:Current Status and Challenges.

Brain and behavior·2025
Same author

Manifestations and Outcomes of Intracerebral Hemorrhage During the COVID-19 Pandemic in China: Multicenter, Longitudinal Cohort Study.

JMIR public health and surveillance·2023
Same author

Prediction of Neurological Deterioration After Intracerebral Hemorrhage: The SIGNALS Score.

Journal of the American Heart Association·2022
Same author

Using Tomoauto: A Protocol for High-throughput Automated Cryo-electron Tomography.

Journal of visualized experiments : JoVE·2016
Same author

MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10.

Clinical immunology (Orlando, Fla.)·2016

Related Experiment Video

Updated: May 12, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.7K

Thrombolysis for acute ischaemic stroke: development and update.

Jiashuo Lin1, Wenbo Zuo1, Huijuan Jin1

  • 1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Brain Communications
|May 7, 2025
PubMed
Summary

New thrombolytic drugs like tenecteplase offer improved options for acute ischemic stroke treatment, showing comparable efficacy and safety to alteplase with easier administration. This review details thrombolytic therapy evolution and effectiveness.

Keywords:
acute ischaemic strokedevelopmentefficacysafetythrombolytics

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

20.6K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.6K

Related Experiment Videos

Last Updated: May 12, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.7K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

20.6K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.6K

Area of Science:

  • Neurology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Thrombolytic therapy is a critical treatment for acute ischemic stroke.
  • Advancements in thrombolytic agents have led to improved treatment strategies.
  • Different generations of thrombolytics (e.g., urokinase, alteplase, tenecteplase) offer distinct pharmacological profiles.

Purpose of the Study:

  • To review the evolution, structural characteristics, and pharmacological properties of thrombolytic drugs.
  • To compare the efficacy and safety of various thrombolytic agents in acute ischemic stroke management.
  • To analyze thrombolytic therapy performance across different patient subgroups and inform clinical practice.

Main Methods:

  • Comprehensive literature review of thrombolytic agents used in acute ischemic stroke.
  • Analysis of structural and pharmacological data of first, second, and third-generation thrombolytics.
  • Examination of clinical trial data on efficacy, safety, and administration of reteplase and tenecteplase versus alteplase.

Main Results:

  • Second-generation alteplase and third-generation tenecteplase offer advantages over first-generation urokinase, including better fibrin specificity and longer half-lives.
  • Tenecteplase demonstrates non-inferiority to alteplase in efficacy and safety, with a more convenient administration.
  • Emerging agents like reteplase and recombinant staphylokinase are gaining clinical interest.

Conclusions:

  • Continuous development of thrombolytics has significantly improved acute ischemic stroke treatment.
  • Tenecteplase presents a favorable alternative to alteplase due to its administration profile.
  • This review provides a scientific foundation for optimizing current thrombolytic therapies and guiding future drug development.